MINOCYCLINE HYDROCHLORIDE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Bacteriostatic antibiotic that reversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
| Metabolism | Hepatic metabolism to multiple metabolites; not extensively metabolized; excreted primarily in urine and feces. Major enzymes: Not well-characterized but may involve CYP enzymes. |
| Excretion | Renal (approximately 10% unchanged; higher in impaired renal function), biliary/fecal (major route via feces as unchanged drug and metabolites, up to 70% overall elimination through hepatobiliary system). |
| Half-life | Terminal elimination half-life: 11–17 hours (mean ~15 hours in normal renal function); prolonged to 18–30 hours in renal impairment; context: allows twice-daily dosing, but accumulation can occur in hepatic/renal dysfunction. |
| Protein binding | 70–80% bound to serum proteins (albumin); minor binding to lipoproteins. |
| Volume of Distribution | 0.6–1.3 L/kg (mean ~1.0 L/kg); extensive tissue penetration, especially into skin, bone, synovial fluid, and CNS; high Vd reflects lipophilicity and intracellular accumulation. |
| Bioavailability | Oral: approximately 90–100% (nearly complete absorption); intravenous: 100% (bioequivalent to oral based on AUC). |
| Onset of Action | Oral: antirheumatic effect within 2–4 weeks; antimicrobial effect: 1–2 hours after first dose for susceptible organisms. Intravenous: rapid (minutes) for antimicrobial effect. |
| Duration of Action | Antimicrobial: 12–24 hours (supports BID dosing); antirheumatic: sustained weeks to months after discontinuing due to tissue accumulation. |
| Molecular Weight | 493.94 |
200 mg orally or intravenously once, followed by 100 mg every 12 hours; maximum 400 mg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 10-50 mL/min: no adjustment; GFR <10 mL/min: reduce dose to 100 mg every 24 hours or avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: reduce dose by 50% or avoid use. |
| Pediatric use | Children ≥8 years: 4 mg/kg orally or intravenously once, then 2 mg/kg every 12 hours; maximum 200 mg/day. |
| Geriatric use | No specific adjustment recommended; monitor renal function and consider lower starting doses due to potential renal impairment. |
| 1st trimester | Contraindicated: Risk of teratogenicity (interference with skeletal development), hepatotoxicity in pregnant women. |
| 2nd trimester | Contraindicated: Use only for life-threatening infections when no alternative exists; may cause permanent discoloration of teeth and bone growth retardation in fetus. |
| 3rd trimester | Contraindicated: Same risks as t2; avoid near term due to potential for pseudotumor cerebri in infant. |
Clinical note
Antacids and calcium supplements decrease absorption Can cause photosensitivity and vestibular toxicity (dizziness vertigo).
| Placental transfer | Minocycline crosses the placenta readily (high degree of transfer). |
| Breastfeeding | Minocycline is excreted into breast milk in small amounts but may cause dental staining and bone growth inhibition in nursing infants. Avoid use during breastfeeding; if necessary, use alternative antibiotic or discontinue breastfeeding. |
■ FDA Black Box Warning
None currently listed in FDA-approved labeling.
| Common Effects | acne |
| Serious Effects |
Hypersensitivity to minocycline or any tetracyclinePregnancy (all trimesters)BreastfeedingChildren under 8 years (risk of permanent tooth discoloration and bone growth inhibition)Severe hepatic impairmentSystemic lupus erythematosus (may exacerbate)
| Precautions | Photosensitivity: Severe sunburn reaction may occur; avoid prolonged sun exposure., Hepatotoxicity: Rare but serious; monitor liver function., Dermatologic reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS)., Autoimmune syndromes: May exacerbate systemic lupus erythematosus or cause drug-induced lupus., Central nervous system effects: Dizziness, vertigo, ataxia, pseudotumor cerebri (especially in women of childbearing age)., Tooth discoloration: Use in children <8 years may cause permanent tooth discoloration., Bone development: Avoid during pregnancy and in children <8 years due to effects on bone growth., Antibiotic-associated colitis: Clostridioides difficile-associated diarrhea (CDAD). |
Loading safety data…
| Lactation Rating | L3 - Moderately Safe (or 'Avoid' based on risk assessment). |
| Teratogenic Risk | Pregnancy Category D. First trimester: No clear association with major malformations, but risk may be low. Second and third trimesters: Use contraindicated due to irreversible fetal tooth discoloration (yellow-gray-brown) and inhibition of bone growth (reversible). Tetracyclines bind to calcium in developing bones and teeth, causing fluorescence and discoloration. Hepatic toxicity in pregnant women reported with IV use, especially with renal impairment. |
| Fetal Monitoring | Monitor maternal liver function tests, renal function, and signs of hepatotoxicity (nausea, vomiting, jaundice). If used inadvertently in late pregnancy, assess infant for dental discoloration and bone growth after birth. No specific fetal monitoring, but ultrasound if concern for bone effects. |
| Fertility Effects | No conclusive evidence of adverse effects on human fertility. Animal studies have shown reduced spermatogenesis and altered reproductive cycles at high doses, but human data limited. May decrease efficacy of oral contraceptives due to reduced enterohepatic circulation of estrogens; alternative contraception recommended. |
| Food/Dietary | Avoid concurrent ingestion with dairy products (milk, cheese, yogurt) and calcium-fortified foods; also avoid iron-containing foods (e.g., spinach, fortified cereals) and antacids with aluminum, calcium, or magnesium. Separate intake by at least 2 hours. |
| Clinical Pearls | Monitor for vestibular adverse effects (dizziness, vertigo, ataxia) which are more common in women; avoid in children under 8 years due to tooth discoloration and bone growth impairment; use with caution in hepatic impairment and lupus patients as minocycline can exacerbate or induce drug-induced lupus; take with a full glass of water to avoid esophageal ulceration; consider pseudo tumor cerebri risk; efficacy in MRSA skin infections. |
| Patient Advice | Take with a full glass of water and avoid lying down for at least 30 minutes after taking to prevent esophageal irritation. · Avoid dairy products, antacids, iron, calcium, magnesium, and zinc supplements within 2 hours of taking minocycline as they may reduce absorption. · Complete the full course of treatment even if you feel better, to prevent resistance. · Report any unusual headaches, vision changes, dizziness, or ringing in the ears. · May cause photosensitivity; use sunscreen and protective clothing, avoid tanning beds. · Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding. · Store at room temperature away from moisture and heat. |